NeoGenomics, Inc. (NEO) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom, providing oncology diagnostic testing, consultative services, and pharmaceutical development support. In late 2024, the Company simplified its reporting structure, consolidating its Clinical Services and Advanced Diagnostics segments into a single operating segment.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Net Revenue | $181,330 | $164,502 | $349,365 | $320,742 |
| Gross Profit | $77,258 | $72,494 | $150,504 | $137,963 |
| Gross Margin | 42.6% | 44.1% | 43.1% | 43.0% |
| Net Loss | $(45,092) | $(18,642) | $(71,015) | $(45,703) |
| Adjusted EBITDA (Non-GAAP) | $10,675 | $10,869 | $17,745 | $14,361 |
| Cash and Cash Equivalents | $154,723 | $367,012 (Dec '24) | End of Period | |
| Working Capital | $292,433 | $294,244 (Dec '24) | End of Period |
Debt & Liquidity: The Company repaid its $201.3 million 2025 Convertible Senior Notes in full on May 1, 2025. As of June 30, 2025, the Company holds $341.1 million in net carrying value of 2028 Convertible Senior Notes. Cash and cash equivalents decreased by approximately $212 million during the six-month period, primarily due to the debt repayment.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 10.2% in Q2 and 8.9% YTD compared to 2024, driven by higher test volumes, strategic reimbursement initiatives, and the acquisition of Pathline, LLC. This was partially offset by lower non-clinical revenue due to macro trends in the pharmaceutical industry.
- Impairment Charges: The Company recorded $20.0 million in impairment charges for both Q2 and YTD 2025. This includes an $11.4 million impairment on the InVisionFirst®-Lung portfolio (intangible assets and inventory) and an $8.2 million impairment related to the planned sale of Trapelo Health, LLC (classified as held for sale).
- Operating Expenses: General and administrative expenses increased 13.3% in Q2, driven by higher software costs, compensation, and transaction costs. Research and development expenses increased 14.4% in Q2.
- Acquisition: Completed the acquisition of Pathline, LLC on April 4, 2025, for approximately $8.3 million in total consideration (including contingent consideration). Pathline contributed approximately $4.7 million in revenue for the quarter.
Guidance, Outlook, and Risks
- Capital Expenditures: Management forecasts capital expenditures for the full year 2025 to be in the range of $30.0 million to $35.0 million.
- Liquidity Outlook: Management believes current cash, marketable securities ($9.0 million), and cash collections are sufficient to fund operations for at least the next 12 months.
- Legal Proceedings:
- Natera Litigation: Ongoing patent infringement litigation regarding the RaDaR® test. A permanent injunction was issued regarding RaDaR® 1.0; trial for RaDaR® 1.1 is expected in October 2025.
- Regulatory Investigation: The Company is under investigation by the OIG and DOJ regarding compliance with federal healthcare laws. A reserve of $11.2 million has been established for potential damages.
- Shareholder Litigation: A class action lawsuit (Goldenberg Matter) alleging misrepresentations regarding business operations and compliance remains pending.
- Regulatory Changes: The "One Big Beautiful Bill Act" (OBBBA) was signed into law on July 4, 2025. The Company is evaluating its impact but does not expect a material impact on financial statements.
Investor Verification Checklist
- Impairment Details: Verify the specific impact of the $20.0 million impairment charges on future cash flows and the strategic rationale for winding down the InVisionFirst®-Lung portfolio.
- Debt Repayment Impact: Confirm the cash burn rate post-repayment of the $201.3 million 2025 Convertible Notes and the sufficiency of the remaining $154.7 million cash balance.
- Legal Reserves: Monitor the $11.2 million regulatory reserve and the status of the Natera patent litigation, specifically the October 2025 trial date.
- Pathline Integration: Assess the revenue contribution and integration progress of the Pathline acquisition against the $4.7 million reported for the quarter.
- Non-GAAP Reconciliation: Review the reconciliation of Net Loss to Adjusted EBITDA, noting the exclusion of significant one-time costs such as CEO transition costs and IP litigation expenses.